GUFIC BIOSCIENCES LTD. Granted Patent in Europe for Omadacycline Tosylate Invention

GUFIC BIOSCIENCES LTD. has been granted a patent in Europe for an invention titled 'A FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE WITH IMPROVED STABILITY'. The patent was granted on January 29, 2025, for a term of 20 years effective from June 5, 2023. Omadacycline Tosylate is approved in the United States for the treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The intimation was received by the Company on January 31, 2025.